Filter By Category
Archives
Share on -
CALOTATUG
Generic Name: CALOTATUG
ABSTRACT -
Calotatug is an investigational monoclonal antibody targeting a tumour-associated antigen or immune checkpoint pathway being evaluated in early-phase oncology trials. It is being assessed for solid tumours or haematological malignancies where its target is overexpressed or dysregulated. Phase I studies are defining safety, pharmacokinetics, and early efficacy signals.
DOSAGE -
Intravenous infusion; flat or weight-based dosing Q2W or Q3W per Phase I escalation protocol.
SIDE EFFECTS -
- Fatigue
- Infusion-related reactions
- Nausea
- Elevated liver enzymes
- Rash
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion hypersensitivity
- Urticaria
- Angioedema
- Anaphylaxis
DRUG INTERACTIONS-
- Concomitant immunosuppressants may reduce efficacy
- Avoid live vaccines
- Additive toxicity with other biologic agents
PREAUTONS–
- Premedicate for infusion reactions
- LFT monitoring recommended
- Effective contraception required
- Use only in clinical trial settings
WARNINGS –
- Immune-mediated toxicities possible
- Embryo-foetal toxicity not excluded
- Report all adverse events through trial pharmacovigilance
Share on -
. Developed by